Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by

Chiara Giommarelli1, Alessandro Corti, Rosanna Supino

  • 1Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy.

Insights

Combining arsenic trioxide with ascorbic acid can overcome melanoma cell resistance to oxidative stress. This strategy targets cellular protection mechanisms, offering a novel approach to enhance cancer therapy effectiveness.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Tumor cells, particularly melanoma, exhibit resistance to oxidative stress, contributing to drug resistance.
  • Melanoma cell clones with differing gamma-glutamyltransferase expression show varied responses to oxidative stress and protective system stimulation.

Purpose of the Study:

  • To investigate the efficacy of combining two prooxidant agents to overcome oxidative stress tolerance in human melanoma cells.
  • To explore the role of gamma-glutamyltransferase and cellular protective mechanisms in melanoma drug resistance.

Main Methods:

  • Utilized two human melanoma cell clones with distinct gamma-glutamyltransferase expression levels.
  • Administered arsenic trioxide and ascorbic acid in combination to assess apoptosis and reactive oxygen species induction.
  • Analyzed catalase activity and the involvement of the ASK1/p38 signaling pathway.

Main Results:

  • The gamma-glutamyltransferase-overexpressing clone showed resistance to arsenic trioxide-induced apoptosis, with low reactive oxygen species and high catalase activity.
  • Combining arsenic trioxide with ascorbic acid sensitized resistant melanoma cells to apoptosis.
  • The sensitization involved the ASK1/p38 axis, regulating catalase expression and apoptosis.

Conclusions:

  • Rational combination of prooxidant agents can effectively overcome cellular tolerance to oxidative stress in melanoma.
  • Targeting cellular protection mechanisms, like catalase activity via the ASK1/p38 axis, is a promising strategy for overcoming drug resistance.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...